-
Abstract Number: 1124
The Direct and Indirect Costs of Illness Associated with Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review
-
Abstract Number: 1125
Health Care Resource Utilization and Costs in Patients with Juvenile Idiopathic Arthritis Treated with Abatacept and Other Targeted Disease Modifying Anti-rheumatic Drugs
-
Abstract Number: 1126
A Medical Assistant Driven Quality Improvement Intervention Increases Rates of DEXA Screening Among RA Patients
-
Abstract Number: 1127
Interventions to Improve Time to Appointment and Outcome Variables in the Pediatric to Adult Transition of Care in Rheumatology
-
Abstract Number: 1128
Physician-Patient Interaction and Medication Adherence in Lupus Nephritis
-
Abstract Number: 1129
Direct Medical and Societal Cost of Opioid Use in Symptomatic Knee Osteoarthritis Patients in the United States
-
Abstract Number: 1130
The Risk of Toxic Retinopathy Among Patients on Hydroxychloroquine
-
Abstract Number: 1131
Loss to Follow-up in Registries of Rheumatic Patients Treated with Biologics: A Potentially Valuable Hidden Real-world Data That Is Being Overlooked?
-
Abstract Number: 1132
Facility-Level Variation in Biologic Disease Modifying Agents for Medicare Enrollees with Rheumatoid Arthritis
-
Abstract Number: 1133
Medicare Spending (2012-2017) on Disease Modifying Agents Commonly Used in Rheumatoid Arthritis
-
Abstract Number: 1134
Medicaid Spending (2013-2017) on Disease Modifying Agents Commonly Used in Rheumatoid Arthritis
-
Abstract Number: 1135
Optimizing the Management of Flares in Patients with Rheumatoid Arthritis with the Help of Non-Physician Providers: Results of a Randomized Controlled Trial
-
Abstract Number: 1136
Improving Access in an Academic Rheumatology Department by Reducing the No Show Rate
-
Abstract Number: 1137
Predictors of Health-Related Quality of Life in Patients with Musculoskeletal Diseases: A Longitudinal Analysis from an Electronic Health Record Database
-
Abstract Number: 1138
Outpatient Costs and Evaluation and Management (E&M) Expenditure Trends in Rheumatoid Arthritis (RA) Patients Treated with Biologic Therapies in US Community Practices
- « Previous Page
- 1
- …
- 76
- 77
- 78
- 79
- 80
- …
- 198
- Next Page »